Abstract
The recent identification of key molecular protagonists involved in osteoclast biology has led to the development of new therapeutic approaches of osteolytic diseases using biological molecules which could compete with bisphosphonate therapy.
MeSH terms
-
Animals
-
Diphosphonates / therapeutic use
-
Drug Design
-
Glycoproteins / therapeutic use
-
Humans
-
Integrin alphaVbeta3 / antagonists & inhibitors
-
Molecular Mimicry
-
Osteolysis / drug therapy*
-
Osteoprotegerin
-
Peptides / chemistry
-
Receptors, Cytoplasmic and Nuclear / therapeutic use
-
Receptors, Tumor Necrosis Factor / therapeutic use
-
Recombinant Proteins / therapeutic use
-
Signal Transduction / drug effects
Substances
-
Diphosphonates
-
Glycoproteins
-
Integrin alphaVbeta3
-
Osteoprotegerin
-
Peptides
-
Receptors, Cytoplasmic and Nuclear
-
Receptors, Tumor Necrosis Factor
-
Recombinant Proteins
-
TNFRSF11B protein, human